# Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression

> **NCT03050736** · PHASE2 · COMPLETED · sponsor: **Kintara Therapeutics, Inc.** · enrollment: 29 (actual)

## Conditions studied

- Glioma
- Glioblastoma
- Glioblastoma Multiforme
- GBM
- Brain Cancer

## Interventions

- **DRUG:** VAL-083 (Dianhydrogalactitol)

## Key facts

- **NCT ID:** NCT03050736
- **Lead sponsor:** Kintara Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-17
- **Primary completion:** 2021-11-22
- **Final completion:** 2024-12-30
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2025-09-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03050736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03050736, "Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03050736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*